[Transient agranulocytosis in the course of treatment with sulfamethoxazole-trimethoprim].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced*; D000743:Anemia, Hemolytic / Q000150:complications; D000890:Anti-Infective Agents / Q000009:adverse effects*; D001853:Bone Marrow / Q000503:physiopathology; D001854:Bone Marrow Cells; D048909:Diabetes Complications; D004338:Drug Combinations; D005493:Folic Acid Antagonists / Q000009:adverse effects*; D006801:Humans; D007958:Leukocyte Count; D007970:Leukopenia / Q000139:chemically induced; D008103:Liver Cirrhosis / Q000150:complications; D011014:Pneumonia / Q000188:drug therapy*; D011725:Pyridines / Q000009:adverse effects*; D013420:Sulfamethoxazole / Q000009:adverse effects*; D013997:Time Factors; D014295:Trimethoprim / Q000009:adverse effects; D014435:Typhoid Fever / Q000188:drug therapy*
D000890:Anti-Infective Agents; D004338:Drug Combinations; D005493:Folic Acid Antagonists; D011725:Pyridines; D014295:Trimethoprim; D013420:Sulfamethoxazole
Agranulocytose transitoire au cours d'un traitement par le sulfaméthoxazole-triméthoprime.